



**MorphoSys US Inc.**  
**Access & Policy**  
470 Atlantic Avenue  
Suite 1401  
Boston, MA 02210

August 6, 2020

***Sent via electronic mail to [ago.highcostprescriptiondrugs@vermont.gov](mailto:ago.highcostprescriptiondrugs@vermont.gov)***

Office of the Attorney General  
State of Vermont  
109 State Street  
Montpelier, Vermont 05609

**Notice of New Prescription Drug: MONJUVI® (tafasitamab-cxix)**

In accordance with 18 V.S.A. § 4637, MorphoSys US Inc. ("MorphoSys") hereby submits to the Office of the Attorney General of the State of Vermont (the "Office") notice that on August 5, 2020, MorphoSys along with our co-promote partner Incyte Corporation, introduced the prescription drug MONJUVI® (tafasitamab-cxix) (NDC 73535-0208-01) to market with a wholesale acquisition cost (WAC) exceeding the threshold set for a specialty drug under the Medicare Part D program. MorphoSys is timely submitting this notice within three calendar days of that date of introduction and will submit a report to the Office as required within 30 calendar days of providing this notice.

Please contact me by email at [christopher.mancill@morphosys.com](mailto:christopher.mancill@morphosys.com) or by phone at (617) 895-8061 if there are any questions concerning this notice regarding the introduction of MONJUVI® to market.

Best regards,

A handwritten signature in blue ink that reads "Chris Mancill". The signature is stylized with a large, looping "C" and "M".

Chris Mancill  
Senior Vice President &  
Head, Access & Policy  
MorphoSys US Inc.